MapLight Therapeutics, Inc. (MPLT) stock forecast and price target
Price $7.25 · data as of November 13, 2026
12-month price target
Average target$26.54
Upside / downside+266.0%
Analysts13
ConsensusNone
Low $13.00Average $26.54High $43.00
Gold marker: average target · white marker: today’s price ($7.25)
Analyst ratings
Strong buy 1Buy 11Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-4.49 | +75.8% | $0 |
| Next fiscal year ends December 31, 2027 | $-3.42 | +23.9% | $15M |
| Quarter after ends December 31, 2026 | $-1.04 | +57.8% | $0 |
Consensus of the analysts covering MapLight Therapeutics, updated daily. In the last 30 days 5 estimates were raised and 0 lowered.
Frequently asked questions
What is the MapLight Therapeutics stock price target?
The average 12-month target from 13 analysts is $26.54, 266.0% above the current price of $7.25 Targets range from $13.00 to $43.00.
Is MapLight Therapeutics a buy according to analysts?
The consensus rating is “None” (1 strong buy, 11 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is MapLight Therapeutics expected to earn?
Analysts expect EPS of $-4.49 for the fiscal year ending December 31, 2026 and $-3.42 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.